FMP
Cellectar Biosciences, Inc.
CLRB
NASDAQ
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
0.264 USD
0.0126 (4.77%)
CLRB Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-47.58M
-32.38M
-25.22M
-22.57M
Net Income
-44.58M
-37.98M
-28.6M
-24.12M
Depreciation & Amortization
291.65k
192.38k
148.44k
149.91k
Deferred Income Taxes
0
0
0
2.94k
Stock Based Compensation
4.27M
2.41M
1.45k
1.12k
Change in Working Capital
-1.73M
3.48M
1.68M
198.76k
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
-1.59M
3.7M
1.62M
411.72k
Other Working Capital
-132.42k
-224.39k
60.21k
-212.96k
Other Non-Cash Items
-5.84M
-471.95k
93.82k
77.72k
CF from Investing Activities
-104.19k
-864.04k
-225.97k
-141.36k
Investments in Property, Plant & Equipment
-104.19k
-864.04k
-225.97k
-141.36k
Net Acquisitions
0
0
0
0
Investment Purchases
0
0
0
0
Sales/Maturities of Investments
0
0
0
0
Other Investing Activites
0
0
0
0
CF from Financing Activities
61.41M
22.94M
9.61M
1.25M
Debt Repayment
0
0
0
0
Common Stock Issued
0
0
9.61M
34.87k
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
61.41M
789.64k
-9.61M
1.21M
Free Cash Flow
-47.69M
-33.24M
-25.45M
-22.71M
Operating Cash Flow
-47.58M
-32.38M
-25.22M
-22.57M
Capital Expenditures
-104.19k
-864.04k
-225.97k
-141.36k
Cash at Beginning of Period
9.56M
19.87M
35.7M
57.17M
Cash at End of Period
23.29M
9.56M
19.87M
35.7M
Net Change In Cash
13.72M
-10.3M
-15.84M
-21.46M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-217.48M
-179.5M
-150.9M
-126.78M
Net Income
-44.58M
-37.98M
-28.6M
-23.97M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-247.34M
-217.48M
-179.5M
-150.9M
Other Distributions
-29.86M
-37.98M
-28.6M
-24.12M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
1.19M
1.59M
978.98k
549.13k
Annual Depreciation
0
192.38k
238.87k
227.64k
Capital Expenditure
-104.19k
-864.04k
-225.97k
-141.36k
Net PPE
1.3M
2.26M
966.08k
462.86k
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
